Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)Trial to evaluate efficacy and safety of lerodalcibep (LIB003) and inclisiran in high risk CVD patients (LIBerate-VI) (NCT05004675)Study of efficacy and safety of lerodalcibep (LIB003) in patients with CVD on statins requiring additional LDL-C reduction (LIBerate-CVD) (NCT04797247)Study to assess the efficacy and safety of lerodalcibep (LIB003) in patients with HeFH on oral lipid therapy needing further LDL-C reduction (LIBerate-FH) (NCT04797104)Study of long term efficacy and safety of lerodalcibep (LIB003) in patients with CVD or high risk for CVD needing further LDL-C Reduction (LIBerate-HR, NCT04806893)Phase 3 study to evaluate the efficacy and safety of lerodalcibep (LIB003) with evolocumab in HoFH (NCT04034485)

Trials

Verve-101

VERVE-101 CRISPR gene editing treatment. read more »

Inclisiran (previously ALN-PCSsc)

Inclisiran is a small interfering RNA (siRNA) which limits production of PCSK9. read more »

Lerodalcibep (LIB003)

Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin.read more »

Alirocumab is being evaluated in the ODYSSEY clinical trial programme including studies in patients with familial hypercholesterolaemia (FH), and patients with hypercholesterolaemia, including those at high cardiovascular risk.read more »

Evolocumab

Evolocumab has been evaluated in the PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations) clinical trial programme.read more »

Bococizumab

Bococizumab: SPIRE clinical trial programme (terminated).read more »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters